Oncolytic Virotherapy最新文献_第7页

Oncolytic viral therapy: targeting cancer stem cells. 溶瘤病毒治疗:靶向癌症干细胞。

IF 6.7

Oncolytic Virotherapy Pub Date : 2014-02-01 DOI: 10.2147/OV.S52749

Tyrel T Smith, Justin C Roth, Gregory K Friedman, G Yancey Gillespie

{"title":"Oncolytic viral therapy: targeting cancer stem cells.","authors":"Tyrel T Smith, Justin C Roth, Gregory K Friedman, G Yancey Gillespie","doi":"10.2147/OV.S52749","DOIUrl":"https://doi.org/10.2147/OV.S52749","url":null,"abstract":"Cancer stem cells (CSCs) are defined as rare populations of tumor-initiating cancer cells that are capable of both self-renewal and differentiation. Extensive research is currently underway to develop therapeutics that target CSCs for cancer therapy, due to their critical role in tumorigenesis, as well as their resistance to chemotherapy and radiotherapy. To this end, oncolytic viruses targeting unique CSC markers, signaling pathways, or the pro-tumor CSC niche offer promising potential as CSCs-destroying agents/therapeutics. We provide a summary of existing knowledge on the biology of CSCs, including their markers and their niche thought to comprise the tumor microenvironment, and then we provide a critical analysis of the potential for targeting CSCs with oncolytic viruses, including herpes simplex virus-1, adenovirus, measles virus, reovirus, and vaccinia virus. Specifically, we review current literature regarding first-generation oncolytic viruses with their innate ability to replicate in CSCs, as well as second-generation viruses engineered to enhance the oncolytic effect and CSC-targeting through transgene expression.","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2014-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S52749","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32346366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. 编码粒细胞-巨噬细胞集落刺激因子的溶瘤疱疹病毒治疗恶性黑色素瘤的关键分析。

IF 6.7

Oncolytic Virotherapy Pub Date : 2014-01-15 eCollection Date: 2014-01-01 DOI: 10.2147/OV.S36701

Tasha Hughes, Robert S Coffin, Caroline E Lilley, Rafael Ponce, Howard L Kaufman

引用次数: 24

Immune cells: more than simple carriers for systemic delivery of oncolytic viruses. 免疫细胞:不仅仅是溶瘤病毒系统传递的简单载体。

IF 6.7

Oncolytic Virotherapy Pub Date : 2014-01-01 DOI: 10.2147/OV.S47143

Samuel Eisenstein, Shu-Hsia Chen, Ping-Ying Pan

引用次数: 9

Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses. 多机制溶瘤病毒治疗中的武装病毒:当前研究和未来发展，重点是痘病毒。

IF 6.7

Oncolytic Virotherapy Pub Date : 2013-12-05 eCollection Date: 2014-01-01 DOI: 10.2147/OV.S36703

Padma Sampath, Steve H Thorne

{"title":"Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.","authors":"Padma Sampath, Steve H Thorne","doi":"10.2147/OV.S36703","DOIUrl":"https://doi.org/10.2147/OV.S36703","url":null,"abstract":"The field of oncolytic virology has made great strides in recent years. However, one key finding has been that the use of viral agents that replicate selectively in tumors is usually insufficient to achieve anything beyond small and transient responses. Instead, like most cancer therapies, oncolytic viruses are most effective in combination with other therapies, which is where they have proven therapeutic effects in clinical and preclinical studies. In cases of some of the smaller RNA viruses, effects can only be achieved through combination regimens with chemotherapy, radiotherapy, or targeted conventional therapies. However, larger DNA viruses are able to express one or more transgenes; thus, therapeutic mechanisms can be built into the viral vector itself. The incorporated approaches into arming oncolytic viruses through transgene expression will be the main focus of this review, including use of immune activators, prodrug converting enzymes, anti-angiogenic factors, and targeting of the stroma. This will focus on poxviruses as model systems with large cloning capacities, which have routinely been used as transgene expression vectors in different settings, including vaccine and oncolytic viral therapy. ","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2013-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S36703","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34747349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs. 溶瘤性疱疹病毒、化疗药物和其他抗癌药物。

IF 6.7

Oncolytic Virotherapy Pub Date : 2013-12-04 eCollection Date: 2013-01-01 DOI: 10.2147/OV.S52601

Lynne Braidwood, Sheila V Graham, Alex Graham, Joe Conner

{"title":"Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.","authors":"Lynne Braidwood, Sheila V Graham, Alex Graham, Joe Conner","doi":"10.2147/OV.S52601","DOIUrl":"https://doi.org/10.2147/OV.S52601","url":null,"abstract":"Oncolytic viruses are emerging as a potential new way of treating cancers. They are selectively replication-competent viruses that propagate only in actively dividing tumor cells but not in normal cells and, as a result, destroy the tumor cells by consequence of lytic infection. At least six different oncolytic herpes simplex viruses (oHSVs) have undergone clinical trials worldwide to date, and they have demonstrated an excellent safety profile and intimations of efficacy. The first pivotal Phase III trial with an oHSV, talimogene laherparepvec (T-Vec [OncoVex(GM-CSF)]), is almost complete, with extremely positive early results reported. Intuitively, therapeutically beneficial interactions between oHSV and chemotherapeutic and targeted therapeutic drugs would be limited as the virus requires actively dividing cells for maximum replication efficiency and most anticancer agents are cytotoxic or cytostatic. However, combinations of such agents display a range of responses, with antagonistic, additive, or, perhaps most surprisingly, synergistic enhancement of antitumor activity. When synergistic interactions in cancer cell killing are observed, chemotherapy dose reductions that achieve the same overall efficacy may be possible, resulting in a valuable reduction of adverse side effects. Therefore, the combination of an oHSV with \"standard-of-care\" drugs makes a logical and reasonable approach to improved therapy, and the addition of a targeted oncolytic therapy with \"standard-of-care\" drugs merits further investigation, both preclinically and in the clinic. Numerous publications report such studies of oncolytic HSV in combination with other drugs, and we review their findings here. Viral interactions with cellular hosts are complex and frequently involve intracellular signaling networks, thus creating diverse opportunities for synergistic or additive combinations with many anticancer drugs. We discuss potential mechanisms that may lead to synergistic interactions. ","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2013-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S52601","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34746448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Cell carriers for oncolytic viruses: current challenges and future directions. 溶瘤病毒的细胞载体:当前的挑战和未来的方向。

IF 6.7

Oncolytic Virotherapy Pub Date : 2013-10-09 eCollection Date: 2013-01-01 DOI: 10.2147/OV.S36623

Dominic G Roy, John C Bell

引用次数: 49

Oncolytic virus therapy for cancer. 溶瘤病毒治疗癌症。

IF 6.7

Oncolytic Virotherapy Pub Date : 2013-09-23 eCollection Date: 2013-01-01 DOI: 10.2147/OV.S38901

Joe Goldufsky, Shanthi Sivendran, Sara Harcharik, Michael Pan, Sebastian Bernardo, Richard H Stern, Philip Friedlander, Carl E Ruby, Yvonne Saenger, Howard L Kaufman

{"title":"Oncolytic virus therapy for cancer.","authors":"Joe Goldufsky, Shanthi Sivendran, Sara Harcharik, Michael Pan, Sebastian Bernardo, Richard H Stern, Philip Friedlander, Carl E Ruby, Yvonne Saenger, Howard L Kaufman","doi":"10.2147/OV.S38901","DOIUrl":"https://doi.org/10.2147/OV.S38901","url":null,"abstract":"The use of oncolytic viruses to treat cancer is based on the selection of tropic tumor viruses or the generation of replication selective vectors that can either directly kill infected tumor cells or increase their susceptibility to cell death and apoptosis through additional exposure to radiation or chemotherapy. In addition, viral vectors can be modified to promote more potent tumor cell death, improve the toxicity profile, and/or generate host antitumor immunity. A variety of viruses have been developed as oncolytic therapeutics, including adenovirus, vaccinia virus, herpesvirus, coxsackie A virus, Newcastle disease virus, and reovirus. The clinical development of oncolytic viral therapy has accelerated in the last few years, with several vectors entering clinical trials for a variety of cancers. In this review, current strategies to optimize the therapeutic effectiveness and safety of the major oncolytic viruses are discussed, and a summary of current clinical trials is provided. Further investigation is needed to characterize better the clinical impact of oncolytic viruses, but there are increasing data demonstrating the potential promise of this approach for the treatment of human and animal cancers. ","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2013-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S38901","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34746446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 50

Oncolytic virotherapy: the questions and the promise. 溶瘤病毒疗法:问题与前景。

IF 6.7

Oncolytic Virotherapy Pub Date : 2013-05-31 eCollection Date: 2013-01-01 DOI: 10.2147/OV.S39609

Laure Aurelian

{"title":"Oncolytic virotherapy: the questions and the promise.","authors":"Laure Aurelian","doi":"10.2147/OV.S39609","DOIUrl":"https://doi.org/10.2147/OV.S39609","url":null,"abstract":"Oncolytic virotherapy is a new strategy to reduce tumor burden through selective virus replication in rapidly proliferating cells. Oncolytic viruses are members of at least ten virus families, each with its advantages and disadvantages. Here, I briefly review the recent advances and key challenges, as exemplified by the best-studied platforms. Recent advances include preclinical proof of feasibility, clinical evidence of tolerability and effectiveness, and the development of new strategies to improve efficacy. These include engineered tumor selectivity and expression of antitumorigenic genes that could function independently of virus replication, identification of combinatorial therapies that accelerate intratumoral virus propagation, and modification of immune responses and vascular delivery for treatment of metastatic disease. Key challenges are to select \"winners\" from the distinct oncolytic platforms that can stimulate anti-cancer immunity without affecting virus replication and can lyse cancer stem cells, which are most likely responsible for tumor maintenance, aggressiveness, and recurrence. Preventing the emergence of resistant tumor cells during virotherapy through the activation of multiple death pathways, the development of a better understanding of the mechanisms of cancer stem-cell lysis, and the development of more meaningful preclinical animal models are additional challenges for the next-generation of engineered viruses. ","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2013-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S39609","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34746445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma. 瘤内黏液瘤病毒治疗免疫活性小鼠黑色素瘤模型的组织学评价。

IF 6.7

Oncolytic Virotherapy Pub Date : 2013-01-01 DOI: 10.2147/OV.S37971

Rosalinda A Doty, Jia Liu, Grant McFadden, Edward J Roy, Amy L MacNeill

{"title":"Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.","authors":"Rosalinda A Doty, Jia Liu, Grant McFadden, Edward J Roy, Amy L MacNeill","doi":"10.2147/OV.S37971","DOIUrl":"https://doi.org/10.2147/OV.S37971","url":null,"abstract":"Two recombinant myxoma viruses (MYXV expressing a fluorescent protein [MYXV-Tred] and MYXV-Tred encoding murine interleukin-15 [MYXV-IL15]) were evaluated for therapeutic effects in an aggressive B16F10 melanoma model in immunocompetent mice. It was hypothesized that continuous expression of IL-15 within a tumor would recruit cytotoxic effector cells to induce an antitumor immune response and improve treatment efficacy. Weekly intratumoral injections were given to evaluate the effect of treatment on the median survival time of C57BL/6 mice bearing established B16F10 melanomas. Mice that received MYXV-Tred or MYXV-IL15 lived significantly longer than mice given treatment controls. Unexpectedly, the median survival time of MYXV-IL15-treated mice was similar to that of MYXV-treated mice. At 1, 2, and 4 days postinoculation, viral plaque assays detected replicating MYXV-Tred and MYXV-IL15 within treated tumors. At these time points in MYXV-IL15-treated tumors, IL-15 concentration, lymphocyte grades, and cluster of differentiation-3+ cell counts were significantly increased when compared to other treatment groups. However, viral titers, recombinant protein expression, and lymphocyte numbers within the tumors diminished rapidly at 7 days postinoculation. These data indicate that treatment with recombinant MYXV should be repeated at least every 4 days to maintain recombinant protein expression within a murine tumor. Additionally, neutrophilic inflammation was significantly increased in MYXV-Tred- and MYXV-IL15-treated tumors at early time points. It is speculated that neutrophilic inflammation induced by intratumoral replication of recombinant MXYV contributes to the antitumoral effect of MYXV treatment in this melanoma model. These findings support the inclusion of neutrophil chemotaxins in recombinant poxvirus oncolytic virotherapy.","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S37971","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33210026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Oncolytic virotherapy for ovarian cancer. 卵巢癌的溶瘤病毒治疗。

IF 6.7

Oncolytic Virotherapy Pub Date : 2012-08-01 DOI: 10.2147/ov.s31626

Shoudong Li, Jessica Tong, Masmudur M Rahman, Trevor G Shepherd, Grant McFadden

引用次数: 15